Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Ben Fredj

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of Clinical Pharmacy and Therapeutics|December 14, 2019
Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosisMohammed Alshaikheid, Amel Chaabane, Nadia Ben Fredj, et al.
The Pharmacogenomics Journal|March 2, 2021
Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patientsMohammed Alshaikheid, Nadia Ben Fredj, Ibtissem Hannachi, et al.
Immunology Letters|November 5, 2016
The association between functional HLA-G 14bp insertion/deletion and +3142 C>G polymorphisms and susceptibility to multiple sclerosisNadia Ben Fredj, Kaouthar Sakly, Daria Bortolotti, et al.
European Journal of Clinical Pharmacology|October 18, 2022
Case series of chronic spontaneous urticaria following COVID-19 vaccines: an unusual skin manifestationNadia Ben-Fredj, Ferdaous Chahed, Najah Ben-Fadhel, et al.
Pharmacogenomics|October 9, 2024
Effects of genetic and clinical factors on thiopurine drugs pharmacokinetics in Tunisian patientsZohra Chadli, Ibtissem Hannachi, Manel Ben Belgacem, et al.
Human Immunology|August 28, 2012
Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosisRoberta Rizzo, Daria Bortolotti, Nadia Ben Fredj, et al.
The Pharmacogenomics Journal|March 18, 2021
Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patientsHelmi Ammar, Zohra Chadli, Ahmed Mhalla, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of Clinical Pharmacy and Therapeutics|December 14, 2019
Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosisMohammed Alshaikheid, Amel Chaabane, Nadia Ben Fredj, et al.
The Pharmacogenomics Journal|March 2, 2021
Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patientsMohammed Alshaikheid, Nadia Ben Fredj, Ibtissem Hannachi, et al.
Immunology Letters|November 5, 2016
The association between functional HLA-G 14bp insertion/deletion and +3142 C>G polymorphisms and susceptibility to multiple sclerosisNadia Ben Fredj, Kaouthar Sakly, Daria Bortolotti, et al.
European Journal of Clinical Pharmacology|October 18, 2022
Case series of chronic spontaneous urticaria following COVID-19 vaccines: an unusual skin manifestationNadia Ben-Fredj, Ferdaous Chahed, Najah Ben-Fadhel, et al.
Pharmacogenomics|October 9, 2024
Effects of genetic and clinical factors on thiopurine drugs pharmacokinetics in Tunisian patientsZohra Chadli, Ibtissem Hannachi, Manel Ben Belgacem, et al.
Human Immunology|August 28, 2012
Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosisRoberta Rizzo, Daria Bortolotti, Nadia Ben Fredj, et al.
The Pharmacogenomics Journal|March 18, 2021
Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patientsHelmi Ammar, Zohra Chadli, Ahmed Mhalla, et al.
Pageof 6